日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

卡格列净在心血管和肾脏疾病一级和二级预防中的应用：来自 CANVAS 项目和 CREDENCE 试验的启示

期刊:Journal of the American Heart Association
影响因子:5.3
doi:10.1161/JAHA.123.031586
Sharma, Abhinav; Razaghizad, Amir; Joury, Abdulaziz; Levin, Adeera; Bajaj, Harpreet S; Mancini, G B John; Wong, Norman C; Slee, April; Ang, Fernando G; Rapattoni, Wally; Neuen, Brendon L; Arnott, Clare; Perkovic, Vlado; Mahaffey, Kenneth W
RED
发表日期：2024
文献求助 收藏

A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m(2) in Ontario, Canada

一项回顾性观察性人群研究，旨在评估加拿大安大略省估计肾小球滤过率<90 mL/min/1.73 m²的2型糖尿病患者的患病率和疾病负担。

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.14294
Rapattoni, Wally; Zante, David; Tomas, Marko; Myageri, Varun; Golden, Shane; Grover, Prerna; Tehrani, Ali; Millson, Brad; Tobe, Sheldon W; Rose, Jennifer B
糖尿病
代谢
发表日期：2021
文献求助 收藏

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice

加拿大卡格列净注册研究：卡格列净在加拿大临床实践中治疗2型糖尿病的有效性和安全性

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.13573
Woo, Vincent; Bell, Alan; Clement, Maureen; Noronha, Luis; Tsoukas, Michael A; Camacho, Fernando; Traina, Shana; Georgijev, Natasha; Culham, Matthew D; Rose, Jennifer B; Rapattoni, Wally; Bajaj, Harpreet S
糖尿病
代谢
发表日期：2019
文献求助 收藏